. 2022 Sep 27;16(1):72. doi: 10.1186/s13065-022-00860-8

Table 3.

Determination of MZH and PYH in different pharmaceutical formulations using the proposed methods using standard addition technique

Drugs	MZH			PYH
Methods	RSM	IDW	FSD	Direct
Navoproxin plus^® tablets^a (found% ± SD)	99.73 ± 0.88	99.58 ± 1.07	99.06 ± 0.83	100.14 ± 0.69
Navoproxin plus ^® tablets^a standard addition (recovery% ± SD)^b	100.18 ± 0.86	99.55 ± 0.78	99.70 ± 0.52	99.54 ± 0.93
Vomidoxine B6^® tablets^a (found% ± SD)	100.09 ± 0.73	99.87 ± 1.22	99.15 ± 1.27	100.63 ± 0.61
Vomidoxine B6® tablets^a standard addition (recovery% ± SD)^b	100.50 ± 1.08	99.36 ± 0.78	98.65 ± 0.41	99.53 ± 1.72
Dizirest B6^® tablets^a (found% ± SD)	99.91 ± 1.01	99.66 ± 1.03	99.51 ± 0.90	101.06 ± 0.79
Dizirest B6^® tablets^a standard addition (recovery% ± SD)^b	99.19 ± 0.77	99.48 ± 1.22	100.13 ± 0.86	100.13 ± 1.05

^aNavoproxin plus, Vomidoxine B6 and Dizirest B6 claimed to contain 25 mg/mL of MZH and 50 mg/mL for PYH

^bAverage of five determinations